Therefore, we hypothesized that MTL-CEBPA sensitizes AML cells to the FLT3 inhibitor, gilteritinib, by limiting leukemic cell proliferation and promoting myeloid differentiation. Here, CEBPA is linked to acute myeloid leukemia.